Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE) was the target of a large increase in short interest in February. As of February 13th, there was short interest totaling 65,459 shares, an increase of 70.1% from the January 29th total of 38,490 shares. Based on an average daily trading volume, of 54,653 shares, the short-interest ratio is presently 1.2 days. Approximately 0.5% of the shares of the stock are short sold. Approximately 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 54,653 shares, the short-interest ratio is presently 1.2 days.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GRCE. Wall Street Zen raised shares of Grace Therapeutics to a “hold” rating in a report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $12.00.

Grace Therapeutics Trading Up 4.1%

Shares of NASDAQ:GRCE traded up $0.17 on Friday, reaching $4.29. 150,021 shares of the company traded hands, compared to its average volume of 110,615. The stock has a market capitalization of $66.37 million, a P/E ratio of -10.72 and a beta of 0.76. The business’s 50-day simple moving average is $3.68 and its 200 day simple moving average is $3.33. Grace Therapeutics has a 52 week low of $1.75 and a 52 week high of $4.30.

Grace Therapeutics (NASDAQ:GRCE) last released its earnings results on Thursday, February 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05). Sell-side analysts expect that Grace Therapeutics will post -1.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Grace Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Millington Financial Advisors LLC purchased a new position in shares of Grace Therapeutics in the second quarter valued at about $59,000. Stratos Wealth Partners LTD. bought a new stake in shares of Grace Therapeutics in the fourth quarter worth about $39,000. XTX Topco Ltd purchased a new position in Grace Therapeutics during the 4th quarter valued at about $106,000. ADAR1 Capital Management LLC increased its holdings in Grace Therapeutics by 83.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 641,988 shares of the company’s stock valued at $2,221,000 after purchasing an additional 291,538 shares during the period. Finally, Renaissance Technologies LLC raised its position in Grace Therapeutics by 53.5% during the 4th quarter. Renaissance Technologies LLC now owns 129,781 shares of the company’s stock valued at $449,000 after purchasing an additional 45,220 shares during the last quarter. Hedge funds and other institutional investors own 6.08% of the company’s stock.

About Grace Therapeutics

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.